NR4A1 and breast cancer: The 5-year survival rate for BC is between 93 and 98%, dependent on patient demographics (e.g., race, ethnicity, age, socioeconomic status, etc.)and tumor morphological properties (e.g., tumor size, local or regional invasion, hormone receptor status, etc.), among other factors.